Synhale Therapeutics Moves Forward with Acquisition of Telaglenastat for Treating Pulmonary Hypertension#None#Boston#Pulmonary_Hypertension#Synhale_Therapeutics#Telaglenastat
Synhale Therapeutics Moves Forward with Acquisition of Telaglenastat for Treating Pulmonary Hypertension
Synhale Therapeutics has acquired Telaglenastat, a key move to enhance the company's clinical programs for pulmonary hypertension, targeting unmet patient needs.
third-news.com
May 1, 2025 at 6:53 PM
Synhale Therapeutics Moves Forward with Acquisition of Telaglenastat for Treating Pulmonary Hypertension#None#Boston#Pulmonary_Hypertension#Synhale_Therapeutics#Telaglenastat